



NewsBREAK | Sept. 22

CMS Announced a 5-Year Increase in Medicare Part B Payment for Certain Biosimilar Biological Products, Effective Oct. 1, 2022

- The Inflation Reduction Act of 2022 (IRA) increases Medicare payments for certain biosimilar biological products to the average sales price (ASP) plus 8% of the ASP of the reference biological for a 5-year period, instead of ASP plus 6%.
- CMS updated the October 2022 ASP Drug Pricing File and released guidance, "Temporary Increase in Medicare Part B Payment for Certain Biosimilar Biological Products," to meet the requirements of the IRA.
- For existing qualifying biosimilar biological products for which payment was made using ASP as of Sept. 30, 2022, the applicable 5-year period begins on Oct. 1, 2022.
- For new qualifying biosimilar biological products for which payment is first made using ASP between Oct. 1, 2022 through Dec. 31, 2027, the applicable 5-year period begins the first day of the calendar quarter of such payment.

More on This Topic

- [Inflation Reduction Act – text](#)
- [Temporary Increase in Medicare Part B Payment for Certain Biosimilar Biological Products](#)
- [2022 ASP Drug Pricing Files](#)

For questions, please reach out to [Tyler Thorne](#).

[Contact Us For Membership Info](#) | [Become a Member](#)

AMCP | 675 North Washington Street, Suite 220 | Alexandria, Virginia 22314
Please [manage your emails here](#).

